+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H1 2019

  • ID: 4760851
  • Drug Pipelines
  • 118 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AptaTargets SL
  • Cyxone AB
  • EyeGene Inc
  • GlaxoSmithKline Plc
  • Immune Design Corp
  • NovImmune SA
  • MORE
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H1 2019

Summary

According to the recently published report 'Toll Like Receptor 4 - Pipeline Review, H1 2019'; Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 37 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes.

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).

The report 'Toll Like Receptor 4 - Pipeline Review, H1 2019' outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 2, 12 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.

Report covers products from therapy areas Oncology, Gastrointestinal, Infectious Disease, Immunology, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Respiratory, Dermatology, Ear Nose Throat Disorders, Mouth and Dental Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Inflammation, Atherosclerosis, Dengue Fever, Kidney Fibrosis, Liver Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Pain, Rheumatoid Arthritis, Sepsis, Solid Tumor, Acute Ischemic Stroke, Acute Liver Failure, Acute Lung Injury, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Bacterial Sepsis, Breast Cancer, Chronic Liver Disease, Complicated Intra-Abdominal Infections, Crohn's Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Drug Addiction, Ebolavirus Infections (Ebola Hemorrhagic Fever), Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Hearing Disorders, Hepatic Injury, Hypopharyngeal Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Laryngeal Cancer, Low Back Pain, Lung Cancer, Marburgvirus Infections (Marburg Hemorrhagic Fever), Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Migraine, Multiple Sclerosis, Necrotizing Enterocolitis, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rosacea, Soft Tissue Sarcoma and Xerostomia.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
  • The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AptaTargets SL
  • Cyxone AB
  • EyeGene Inc
  • GlaxoSmithKline Plc
  • Immune Design Corp
  • NovImmune SA
  • MORE
Introduction

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Indications, H1 2019 (Contd..2), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1)

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Products under Development by Companies, H1 2019 (Contd..3), H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by AptaTargets SL, H1 2019

Pipeline by Batu Biologics Inc, H1 2019

Pipeline by Cyxone AB, H1 2019

Pipeline by Eisai Co Ltd, H1 2019

Pipeline by eTheRNA Immunotherapies NV, H1 2019

Pipeline by EyeGene Inc, H1 2019

Pipeline by GigaGen Inc, H1 2019

Pipeline by GlaxoSmithKline Plc, H1 2019

Pipeline by Harbor Therapeutics Inc, H1 2019

Pipeline by Immune Design Corp, H1 2019

Pipeline by Immunovo BV, H1 2019

Pipeline by NovImmune SA, H1 2019

Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2019

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Pipeline by Vascular Biogenics Ltd, H1 2019

Dormant Products, H1 2019

Discontinued Products, H1 2019

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AptaTargets SL
  • Batu Biologics Inc
  • Cyxone AB
  • Eisai Co Ltd
  • eTheRNA Immunotherapies NV
  • EyeGene Inc
  • GigaGen Inc
  • GlaxoSmithKline Plc
  • Harbor Therapeutics Inc
  • Immune Design Corp
  • Immunovo BV
  • NovImmune SA
  • TaiwanJ Pharmaceuticals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Vascular Biogenics Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4760851
Adroll
adroll